A new trading day began on Friday, with Cardiff Oncology Inc (NASDAQ: CRDF) stock price up 3.78% from the previous day of trading, before settling in for the closing price of $2.38. CRDF’s price has ranged from $2.01 to $5.96 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 24.32% over the last five years. Meanwhile, its annual earnings per share averaged 16.87%. With a float of $59.79 million, this company’s outstanding shares have now reached $66.52 million.
The firm has a total of 33 workers. Let’s measure their productivity. In terms of profitability, gross margin is 69.74%, operating margin of -7112.72%, and the pretax margin is -6642.84%.
Cardiff Oncology Inc (CRDF) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Cardiff Oncology Inc is 10.13%, while institutional ownership is 34.43%. The most recent insider transaction that took place on Dec 17 ’24, was worth 14,905. In this transaction Chief Financial Officer of this company bought 2,752 shares at a rate of $5.42, taking the stock ownership to the 65,316 shares. Before that another transaction happened on Dec 18 ’24, when Company’s Chief Financial Officer bought 2,400 for $5.00, making the entire transaction worth $12,000. This insider now owns 67,716 shares in total.
Cardiff Oncology Inc (CRDF) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.2 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 16.87% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -9.85% during the next five years compared to 19.36% growth over the previous five years of trading.
Cardiff Oncology Inc (NASDAQ: CRDF) Trading Performance Indicators
Here are Cardiff Oncology Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 7.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 241.62.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.95, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.95 in one year’s time.
Technical Analysis of Cardiff Oncology Inc (CRDF)
Analysing the last 5-days average volume posted by the [Cardiff Oncology Inc, CRDF], we can find that recorded value of 2.12 million was better than the volume posted last year of 1.2 million. As of the previous 9 days, the stock’s Stochastic %D was 10.66%. Additionally, its Average True Range was 0.27.
During the past 100 days, Cardiff Oncology Inc’s (CRDF) raw stochastic average was set at 6.21%, which indicates a significant decrease from 7.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.54% in the past 14 days, which was lower than the 124.31% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.83, while its 200-day Moving Average is $3.10. Now, the first resistance to watch is $2.57. This is followed by the second major resistance level at $2.66. The third major resistance level sits at $2.77. If the price goes on to break the first support level at $2.37, it is likely to go to the next support level at $2.26. Should the price break the second support level, the third support level stands at $2.17.
Cardiff Oncology Inc (NASDAQ: CRDF) Key Stats
With a market capitalization of 164.30 million, the company has a total of 66,524K Shares Outstanding. Currently, annual sales are 680 K while annual income is -45,430 K. The company’s previous quarter sales were 150 K while its latest quarter income was -11,790 K.
